Cargando…

Targeting SHP2 phosphatase in Myeloproliferative Neoplasms

Detalles Bibliográficos
Autores principales:	Mali, Raghuveer Singh, Chan, Rebecca, Kapur, Reuben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717955/ https://www.ncbi.nlm.nih.gov/pubmed/23165317

Ejemplares similares

Targeting Rho Associated Kinases in Leukemia and Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012)

Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase
por: Zeng, Li-Fan, et al.
Publicado: (2014)

Role of intracellular tyrosines in activating KIT induced myeloproliferative disease
por: Ma, Peilin, et al.
Publicado: (2012)

S209: TARGETING THE SRC HOMOLOGY 2 DOMAIN-CONTAINING PHOSPHATASE SHP2 ENHANCES THE THERAPEUTIC EFFICACY OF JAK INHIBITION IN MYELOPROLIFERATIVE NEOPLASMS
por: Jungius, Sarah, et al.
Publicado: (2023)

Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms
por: Pandey, Ruchi, et al.
Publicado: (2015)

Unique and redundant roles of class I(A) PI3Kinase regulatory subunits in mast cell development
por: Mali, Raghuveer Singh, et al.
Publicado: (2013)

p53 as a target in myeloproliferative neoplasms
por: Lu, Min, et al.
Publicado: (2012)

Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia
por: Richine, Briana M., et al.
Publicado: (2016)

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Rapid development of myeloproliferative neoplasm in mice with Ptpn11(D61Y) mutation and haploinsufficient for Dnmt3a
por: Deng, Lisa, et al.
Publicado: (2017)

Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia-negative myeloproliferative neoplasm
por: Zhang, Min Yue, et al.
Publicado: (2013)

Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice
por: Sharma, Namit, et al.
Publicado: (2014)

Crossing the Borders: An Integrated Approach to Myeloproliferative Neoplasms and Mastocytoses
por: Pizzi, Marco
Publicado: (2021)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
por: Song, Zhendong, et al.
Publicado: (2021)

Pulmonary Hypertension in Myeloproliferative Neoplasms: New Insights and Unexplored Horizons
por: Leiva, Orly, et al.
Publicado: (2023)

Activating Mutations in Protein Tyrosine Phosphatase Ptpn11 (Shp2) Enhance Reactive Oxygen Species Production That Contributes to Myeloproliferative Disorder
por: Xu, Dan, et al.
Publicado: (2013)

Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice
por: Deng, Lisa, et al.
Publicado: (2017)

SHP2 phosphatase as a novel therapeutic target for melanoma treatment
por: Zhang, Ruo-Yu, et al.
Publicado: (2016)

The Tyrosine Phosphatase SHP2: A New Target for Insulin Resistance?
por: Saint-Laurent, Céline, et al.
Publicado: (2022)

Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms
por: Purwar, Shubhrat, et al.
Publicado: (2023)

“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms
por: Gleitz, Hélène F.E., et al.
Publicado: (2022)

Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

AKT is a therapeutic target in myeloproliferative neoplasms
por: Khan, Irum, et al.
Publicado: (2013)

Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms
por: Brkic, Sime, et al.
Publicado: (2020)

Low neutrophil alkaline phosphatase score is a new aspect of calreticulin-mutated myeloproliferative neoplasms
por: Kondo, Toshinori, et al.
Publicado: (2016)

Inhibition of SHP2 and SHP1 Protein Tyrosine Phosphatase Activity by Chemically Induced Dimerization
por: Buck, Sara J. S., et al.
Publicado: (2022)

Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth
por: Wang, Yuyi, et al.
Publicado: (2021)

The function of Shp2 tyrosine phosphatase in the dispersal of acetylcholine receptor clusters
por: Qian, Yueping K, et al.
Publicado: (2008)

The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Hematopoietic Progenitor Hyperproliferation and Malignant Disease In Vivo
por: Nabinger, Sarah C., et al.
Publicado: (2012)

Acute myocardial infarction in myeloproliferative neoplasms
por: Manan, Muhammad Romail, et al.
Publicado: (2023)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mmip2mpc957fmrrn6p39r2jhao